NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) between January 5, 2023 and June 3, 2025, inclusive. For more information, submit a form at Neogen Corporation Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call u ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Petco Health and Wellness Company, Inc. due to allegations of violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by August 29, 2025 [3][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Petco between January 14, 2021, and June 5, 2025, to discuss their legal options [1][3]. - A federal securities class action has been filed against Petco, with a reminder of the August 29, 2025, deadline for seeking lead plaintiff status [3][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Allegations Against Petco - The complaint alleges that Petco and its executives made false and misleading statements regarding the sustainability of its pandemic-related growth and business model [5]. - Specific allegations include overstating the strength of Petco's product strategy and downplaying the severity of operational issues [5]. - The complaint claims that these misrepresentations led to an overestimation of Petco's ability to achieve sustainable, profitable growth [5]. Group 3: Financial Performance - On June 5, 2025, Petco reported first-quarter financial results, revealing net sales of $1.5 billion, which is a 2.3% decline year-over-year [6]. - Following the financial report, Petco's stock price dropped by $0.85 per share, or 23.34%, closing at $2.78 per share on June 6, 2025 [6].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Centene Corporation due to misleading statements regarding the company's enrollment and morbidity rates, which led to significant stock price declines [3][5]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi is encouraging investors who suffered losses in Centene to contact them for legal options, particularly those who purchased securities between December 12, 2024, and June 30, 2025 [1][3]. - A federal securities class action has been filed against Centene, with a deadline of September 8, 2025, for investors to seek the role of lead plaintiff [3][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Company Performance and Stock Impact - Centene provided positive statements to investors while concealing adverse facts about its enrollment and morbidity rates, leading to a significant loss of investor trust [5]. - On July 1, 2025, Centene withdrew its 2025 guidance, stating that its market growth across 22 states was lower than expected, resulting in a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [5]. - Following this announcement, Centene's stock price plummeted from $56.65 per share to $33.78 per share, marking a decline of 40.4% in just one day [6].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Biohaven Ltd. securities, alleging misleading statements regarding the company's drug regulatory prospects and clinical efficacy during the specified Class Period [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to Biohaven Ltd. securities purchased between March 24, 2023, and May 14, 2025 [1]. - Allegations include that Biohaven overstated the regulatory prospects of its drug troriluzole for treating spinocerebellar ataxia and the efficacy of BHV-7000 for bipolar disorder, which could negatively impact the company's business and financial condition [5]. Group 2: Participation Information - Investors who purchased Biohaven securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly [3][6]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A securities class action lawsuit has been filed against Centene Corporation for allegedly making materially false and misleading statements regarding its business operations and market performance during the specified Class Period from December 12, 2024, to June 30, 2025 [1][2]. Group 1: Allegations Against Centene - The lawsuit claims that Centene's management misrepresented the company's marketplace share, indicating lower-than-expected enrollment and increased market morbidity [2]. - It is alleged that the statements made by Centene's management about the company's business and prospects were materially false and lacked a reasonable basis throughout the Class Period [2]. Group 2: Lead Plaintiff Process - Investors in Centene have until September 8, 2025, to seek appointment as a lead plaintiff representative in the class action, which involves directing the litigation on behalf of all class members [3]. - The lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is a law firm that specializes in prosecuting class actions and has a reputation for recovering significant amounts for victims of corporate misconduct [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Centene Corporation securities during the specified Class Period, indicating potential legal issues for the company related to misleading statements about its financial performance [1][5]. Group 1: Lawsuit Details - The class action lawsuit is filed for investors who purchased Centene common stock between December 12, 2024, and June 30, 2025, and aims to provide compensation without out-of-pocket fees through a contingency fee arrangement [2][5]. - The lawsuit alleges that Centene's management provided materially false and misleading information regarding the company's expected revenue guidance and adjusted diluted earnings per share (EPS) for the 2025 fiscal year, while concealing adverse facts about enrollment and morbidity rates [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions, highlighting the Rosen Law Firm's achievements in this area, including significant settlements and recognition in the legal community [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone, showcasing its capability in handling such cases [4]. Group 3: Next Steps for Investors - Investors wishing to join the class action can do so by visiting the provided link or contacting the firm directly for more information [3][6]. - It is noted that no class has been certified yet, meaning investors are not represented unless they retain counsel, and participation as a lead plaintiff is not necessary for potential recovery [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Vestis Corporation during the specified class period of the upcoming lead plaintiff deadline on August 8, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Vestis securities between May 2, 2024, and May 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the August 8, 2025 deadline [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Case Allegations - The lawsuit alleges that Vestis Corporation provided misleading statements about its business growth potential while concealing material adverse facts regarding its ability to execute strategic initiatives aimed at improving customer experience and revenue growth [4]. - When the true state of affairs became known, investors reportedly suffered damages [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 21, 2025 [3]. Group 2: Case Allegations - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customers' ad spending to closed platforms where DoubleVerify's capabilities were limited [5]. - It is claimed that the development of technology for closed platforms was more expensive and time-consuming than disclosed, impacting the monetization of DoubleVerify's high-margin advertising optimization services [5]. - The lawsuit also states that DoubleVerify's competitors were better positioned to incorporate AI into their offerings, adversely affecting DoubleVerify's competitive edge and profits [5]. - Additional allegations include systematic overbilling of customers for ad impressions served to declared bots and misleading risk disclosures that characterized adverse facts as mere possibilities [5].

SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- On June 25, 2025, securities class action lawsuits were filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the company’s executives. The cases seeks to represent investors who purchased or otherwise acquired Hims & Hers securities between April 29, 2025 and June 23, 2025. The lawsuits follow an announcement by Novo Nordisk, the Danish maker of the FDA-approved weight-loss medication Wegovy® (a GLP-1 treatment for obesity), that it terminated i ...

SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- When, on May 27, 2025, Rocket Pharmaceuticals (NASDAQ: RCKT) revealed that the FDA put a clinical hold on its Phase 2 pivotal trial for RP-A501, an experimental therapy intended to treat patients with a rare gene disorder called Danon disease, investors in the company’s shares saw their investment crash over 60% that day. Danon disease is a multi-organ lysosomal-associated disorder leading to early death due to heart disorder. Since the May 27 announcement, a ...